MDOBX Performance — Developing Opportunity Portfolio, Class C
Data updated: 2026-08-21
MDOBX returned +15.12% year to date and +9.47% over one year to Jun 2026. Annualised returns are +12.94% over 3 years and −3.72% over 5 years. The fund trailed its Emerging Markets Equity category average: $100 invested three years ago grew to $144, against $179 for the category, and to $109 over one year, against $141. Volatility over the past three years was 18.05% a year. In the 12 months to Jun 2026 the fund lost a net $20.5M, and assets reached $26.86M.
MDOBX Growth of $100
What $100 invested in Developing Opportunity Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | MDOBX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $109 | $141 |
| 3 years (Jul 2023 – Jun 2026) | $144 | $179 |
| 5 years (Jul 2021 – Jun 2026) | $83 | $144 |
| Since data start (Feb 2020 – Jun 2026) | $118 | $191 |
MDOBX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +15.12% |
| 1 year | +9.47% |
| 3 years (annualised) | +12.94% |
| 5 years (annualised) | −3.72% |
MDOBX Annual Returns
Calendar-year total returns of Developing Opportunity Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +15.12% |
| 2025 | +7.11% |
| 2024 | +15.57% |
| 2023 | +4.15% |
| 2022 | −31.09% |
| 2021 | −19.57% |
| 2020 (Feb–Dec) | +43.59% |
MDOBX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.5% | +0.1% | −12.4% | +13.6% | +11.1% | +1.6% | — | — | — | — | — | — |
| 2025 | +1.5% | +0.5% | +0.3% | +2.9% | +2.8% | +4.2% | −2.6% | +1.9% | +5.2% | −1.9% | −6.1% | −1.2% |
| 2024 | −6.4% | +6.1% | +2.5% | +3.8% | +2.6% | −1.1% | −1.9% | +4.7% | +10.8% | −0.5% | −0.2% | −4.7% |
| 2023 | +9.2% | −5.1% | +1.9% | −3.1% | −3.1% | +3.8% | +6.3% | −4.2% | −4.5% | −4.3% | +6.2% | +2.4% |
| 2022 | −7.4% | −4.9% | −8.2% | −9.5% | −3.3% | −5.0% | +3.2% | +2.1% | −8.4% | −7.7% | +17.2% | −1.7% |
| 2021 | +4.6% | +0.8% | −7.2% | +0.9% | −0.3% | +1.1% | −13.5% | +3.4% | −4.5% | +2.8% | −7.9% | 0.0% |
| 2020 | — | −6.3% | −11.7% | +7.6% | +8.3% | +9.5% | +11.7% | +9.1% | −3.3% | +1.7% | +7.1% | +6.0% |
MDOBX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 18.05%
- 3-year Sharpe ratio: 0.47 (vs 4.5% risk-free rate)
- Best month: +13.56% (Apr 2026)
- Worst month: −12.44% (Mar 2026)
MDOBX Fund Flows
Monthly money in and out of Developing Opportunity Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$20.5M
- 12-month gross sales (incl. reinvestments): $39.1M
- Sales ÷ redemptions: 0.66×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $155K | $938K | −$783K |
| May 2026 | $572K | $34.0M | −$33.5M |
| Apr 2026 | $962K | $2.9M | −$1.9M |
| Mar 2026 | $7.9M | $1.0M | $6.9M |
| Feb 2026 | $373K | $12.7M | −$12.4M |
| Jan 2026 | $2.1M | $3.6M | −$1.5M |
| Dec 2025 | $2.4M | $1.3M | $1.1M |
| Nov 2025 | $19.4M | $397K | $19.0M |
| Oct 2025 | $708K | $547K | $162K |
| Sep 2025 | $1.8M | $1.1M | $736K |
| Aug 2025 | $2.5M | $681K | $1.8M |
| Jul 2025 | $234K | $480K | −$246K |
MDOBX Assets Under Management
Net assets of Developing Opportunity Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $26.86M |
| 2026-03-31 | $51.28M |
| 2025-12-31 | $62.81M |
| 2025-09-30 | $46.69M |
| 2025-06-30 | $42.32M |
| 2025-03-31 | $43.53M |
| 2024-12-31 | $30.92M |
| 2024-09-30 | $35.67M |
| 2024-06-30 | $32.35M |
| 2024-03-31 | $35.50M |
| 2023-12-31 | $35.35M |
| 2023-09-30 | $39.82M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.